Mirion Technologies, Inc.
Financials
Valuation Metrics
Mirion Technologies, Inc.'s Market Cap is $3.86B. At end of 2025 it was $5.72B. Ranked #1530 of 3,121 in US market (top 49%), #995 of 1,658 on NYSE (top 60%), #151 of 242 in Capital Goods (top 62%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.86B | US#1,530/3,121 Sec#151/242 |
| Revenue | $1.02B | US#1,869/3,121 Sec#180/242 |
| Net Income | $25M | US#2,071/3,121 Sec#180/242 |
| Total Assets | $3.52B | US#1,702/3,121 Sec#133/242 |
| Net Assets | $1.83B | US#1,312/3,121 Sec#110/242 |
| Employees | 3,281 | US#1,442/3,121 Sec#164/242 |
| Value | ||
| P/E | 157.38x | US#2,165/3,121 Sec#189/242 |
| P/B | 2.11x | US#1,353/3,121 Sec#67/242 |
| PEG | 1.09x | US#883/3,121 Sec#71/242 |
| P/S | 3.76x | US#2,040/3,121 Sec#174/242 |
| EV/EBITDA | 21.70x | US#1,991/3,121 Sec#154/242 |
| FCF Yield | 3.55% | US#1,744/3,121 Sec#127/242 |
| Profitability | ||
| ROE | 1.34% | US#2,071/3,121 Sec#189/242 |
| ROA | 0.70% | US#2,091/3,121 Sec#192/242 |
| Op. Margin | 5.32% | US#1,962/3,121 Sec#171/242 |
| Revenue Growth | 15.68% | US#877/3,121 Sec#80/242 |
| Earnings Growth | 145.00% | US#216/3,121 Sec#13/242 |
| Financial Health | ||
| Debt Ratio | 90.13% | US#993/3,121 Sec#79/242 |
| Total Debt | $1.23B | US#1,431/3,121 Sec#105/242 |
| FCF | $137M | US#1,590/3,121 Sec#136/242 |
| Cash | $419M | US#1,185/3,121 Sec#86/242 |
| Current Ratio | 3.20x | US#737/3,121 Sec#44/242 |
| Net Debt/EBITDA | 3.78x | US#1,801/3,121 Sec#175/242 |
| Performance | ||
| 1Y Return | -35.93% | US#2,590/3,121 Sec#207/242 |
| 1M Return | 1.03% | US#423/3,121 Sec#17/242 |
| From 52W High | -47.95% | US#2,629/3,121 Sec#195/242 |
| 1Y MDD | -51.60% | US#2,522/3,121 Sec#196/242 |
| Trading | ||
| Volume | 2,065,423 shares | US#582/3,121 Sec#30/242 |
| Trading Value | $33M | US#1,289/3,121 Sec#133/242 |
| Per Share | ||
| EPS | $0.10 | US#2,089/3,121 Sec#191/242 |
| BPS | $7.46 | US#2,049/3,121 Sec#191/242 |
Company Info
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company also offers include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.